Quick Answer
Emergent BioSolutions Inc. reported Net Income Loss of -$190.60 million for the year ending 2024.
- Emergent BioSolutions Inc. showed an increase of +74.9% in Net Income Loss from 2023 to 2024.
- This data is from Emergent BioSolutions Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2025.
- XBRL data for this metric is available from 2009 to 2024 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$20.24 million | Q2 2014: $5.03 million | Q3 2014: $21.83 million | Q4 2014: $30.12 million | Q1 2015: -$21.52 million | Q2 2015: $14.10 million | Q3 2015: $36.94 million | Q4 2015: $33.35 million | Q1 2016: $3.99 million | Q2 2016: -$10.95 million | Q3 2016: $21.34 million | Q1 2017: $10.49 million | Q2 2017: $4.62 million | Q3 2017: $33.55 million | Q1 2018: -$4.90 million | Q2 2018: $50.10 million | Q3 2018: $20.90 million | Q4 2018: -$3.40 million | Q1 2019: -$26.10 million | Q2 2019: -$9.50 million | Q3 2019: $43.20 million | Q4 2019: $46.90 million | Q1 2020: -$12.50 million | Q2 2020: $92.70 million | Q3 2020: $39.50 million | Q4 2020: $185.40 million | Q1 2021: $69.70 million | Q2 2021: $4.60 million | Q3 2021: -$32.70 million | Q1 2022: -$4.60 million | Q2 2022: -$52.90 million | Q3 2022: -$87.10 million | Q1 2023: -$186.20 million | Q2 2023: -$261.40 million | Q3 2023: -$263.40 million | Q1 2024: $9.00 million | Q2 2024: -$283.10 million | Q3 2024: $114.80 million | Q1 2025: $68.00 million | Q2 2025: -$12.00 million | Q3 2025: $51.20 million.
- Over the full 16 years of available data (2009 to 2024), Emergent BioSolutions Inc.'s Net Income Loss has declined by 712.0%.
- Historical annual values: Fiscal year 2024: -$190.60 million | Fiscal year 2023: -$760.50 million | Fiscal year 2022: -$211.60 million | Fiscal year 2021: $219.50 million | Fiscal year 2020: $305.10 million | Fiscal year 2019: $54.50 million | Fiscal year 2018: $62.70 million | Fiscal year 2017: $82.60 million | Fiscal year 2016: $51.80 million | Fiscal year 2015: $62.87 million | Fiscal year 2014: $36.74 million | Fiscal year 2013: $31.14 million | Fiscal year 2012: $23.52 million | Fiscal year 2011: $23.02 million | Fiscal year 2010: $51.70 million | Fiscal year 2009: $31.14 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: